• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Conformational switches in the VPAC(1) receptor.VPAC(1) 受体的构象开关。
Br J Pharmacol. 2012 May;166(1):79-84. doi: 10.1111/j.1476-5381.2011.01616.x.
2
Localisation of VIP-binding sites exhibiting properties of VPAC receptors in chromaffin cells of rainbow trout (Oncorhynchus mykiss).虹鳟(Oncorhynchus mykiss)嗜铬细胞中表现出VPAC受体特性的血管活性肠肽结合位点的定位。
J Exp Biol. 2003 Jun;206(Pt 11):1917-27. doi: 10.1242/jeb.00350.
3
Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.一种新型VPAC(1)选择性激动剂的表征以及参与羧基末端肽识别的受体结构域的鉴定。
Br J Pharmacol. 2000 Jun;130(4):819-26. doi: 10.1038/sj.bjp.0703384.
4
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽(PACAP)的VPAC受体的分子药理学与结构
Regul Pept. 2002 Oct 15;108(2-3):165-73. doi: 10.1016/s0167-0115(02)00099-x.
5
Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.血管活性肠肽、垂体腺苷酸环化酶激活肽及其受体在人肾上腺中的表达与功能
J Clin Endocrinol Metab. 2002 Jun;87(6):2575-80. doi: 10.1210/jcem.87.6.8571.
6
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.血管活性肠肽和垂体腺苷酸环化酶激活肽受体的药理学和功能:国际药理学联合会评论 1。
Br J Pharmacol. 2012 May;166(1):4-17. doi: 10.1111/j.1476-5381.2012.01871.x.
7
Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.垂体腺苷酸环化酶激活多肽、血管活性肠肽及其受体:在意大利壁蜥肾上腺分泌中的分布及作用
J Endocrinol. 2008 Feb;196(2):291-303. doi: 10.1677/JOE-07-0127.
8
VPAC and PAC receptors: From ligands to function.血管活性肠肽(VPAC)和垂体腺苷酸环化酶激活肽(PAC)受体:从配体到功能
Pharmacol Ther. 2009 Mar;121(3):294-316. doi: 10.1016/j.pharmthera.2008.11.006. Epub 2008 Dec 6.
9
VPAC receptors for VIP and PACAP.血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽(PACAP)的VPAC受体
Recept Channels. 2002;8(3-4):137-53.
10
Structural and functional identification of the pituitary adenylate cyclase-activating polypeptide receptor VPAC2 from the frog Rana tigrina rugulosa.虎纹蛙垂体腺苷酸环化酶激活多肽受体VPAC2的结构与功能鉴定
J Mol Endocrinol. 2001 Oct;27(2):229-38. doi: 10.1677/jme.0.0270229.

引用本文的文献

1
Vasoactive Intestinal Peptide (VIP) Protects Nile Tilapia () against Infection.血管活性肠肽(VIP)可保护尼罗罗非鱼()抵抗感染。
Int J Mol Sci. 2022 Nov 28;23(23):14895. doi: 10.3390/ijms232314895.
2
Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor.描绘B类G蛋白偶联受体胰高血糖素受体的激活机制和构象变化情况。
Comput Struct Biotechnol J. 2022 Jan 20;20:628-639. doi: 10.1016/j.csbj.2022.01.015. eCollection 2022.
3
A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures.胰高血糖素样肽-1受体核心中的氢键极性网络是偏向激动作用的支点:来自B类晶体结构的启示。
Mol Pharmacol. 2016 Mar;89(3):335-47. doi: 10.1124/mol.115.101246. Epub 2015 Dec 23.
4
Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.分泌素家族(B 类)G 蛋白偶联受体——从分子到临床的视角。
Br J Pharmacol. 2012 May;166(1):1-3. doi: 10.1111/j.1476-5381.2011.01810.x.

本文引用的文献

1
Structure of an agonist-bound human A2A adenosine receptor.激动剂结合的人 A2A 腺苷受体结构。
Science. 2011 Apr 15;332(6027):322-7. doi: 10.1126/science.1202793. Epub 2011 Mar 10.
2
Structure and function of an irreversible agonist-β(2) adrenoceptor complex.不可逆激动剂-β(2)肾上腺素能受体复合物的结构与功能。
Nature. 2011 Jan 13;469(7329):236-40. doi: 10.1038/nature09665.
3
Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism.CGRP 受体胞外结构域复合物的晶体结构,一种 B 类 GPCR,揭示了药物拮抗的位点。
Structure. 2010 Sep 8;18(9):1083-93. doi: 10.1016/j.str.2010.05.014.
4
Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation.证据表明,跨膜螺旋 2、3 和 7 中的保守残基之间的相互作用对于人类 VPAC1 受体的激活至关重要。
Mol Pharmacol. 2010 Sep;78(3):394-401. doi: 10.1124/mol.110.063578. Epub 2010 Jun 23.
5
VPAC1 receptor binding site: contribution of photoaffinity labeling approach.VPAC1 受体结合位点:光亲和标记方法的贡献。
Neuropeptides. 2010 Apr;44(2):127-32. doi: 10.1016/j.npep.2009.11.008. Epub 2009 Dec 23.
6
Identification and characterization of a small molecule antagonist of human VPAC(2) receptor.鉴定和表征人 VPAC(2) 受体的小分子拮抗剂。
Mol Pharmacol. 2010 Jan;77(1):95-101. doi: 10.1124/mol.109.060137. Epub 2009 Oct 23.
7
The structure and function of G-protein-coupled receptors.G蛋白偶联受体的结构与功能。
Nature. 2009 May 21;459(7245):356-63. doi: 10.1038/nature08144.
8
VPAC and PAC receptors: From ligands to function.血管活性肠肽(VPAC)和垂体腺苷酸环化酶激活肽(PAC)受体:从配体到功能
Pharmacol Ther. 2009 Mar;121(3):294-316. doi: 10.1016/j.pharmthera.2008.11.006. Epub 2008 Dec 6.
9
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.与拮抗剂结合的人A2A腺苷受体的2.6埃晶体结构。
Science. 2008 Nov 21;322(5905):1211-7. doi: 10.1126/science.1164772. Epub 2008 Oct 2.
10
Crystal structure of opsin in its G-protein-interacting conformation.视蛋白处于与G蛋白相互作用构象时的晶体结构。
Nature. 2008 Sep 25;455(7212):497-502. doi: 10.1038/nature07330.

VPAC(1) 受体的构象开关。

Conformational switches in the VPAC(1) receptor.

机构信息

Université Libre de Bruxelles, Brussels, Belgium.

出版信息

Br J Pharmacol. 2012 May;166(1):79-84. doi: 10.1111/j.1476-5381.2011.01616.x.

DOI:10.1111/j.1476-5381.2011.01616.x
PMID:21806602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3415639/
Abstract

The vasoactive intestinal peptide receptor 1 (VPAC(1) ) belongs to family B of GPCRs and is activated upon binding of vasoactive intestinal peptide (VIP) and pituitary AC-activating polypeptide neuropeptides. Widely distributed throughout body, VPAC(1) plays important regulatory roles in human physiology and physiopathology. Like most members of the GPCR-B family, VPAC(1) receptor is predicted to follow the actual paradigm of a common 'two-domain' model of natural ligand action. However the precise structural basis for ligand binding, receptor activation and signal transduction are still incompletely understood due in part to the absence of X-ray crystal structure of the whole receptor and to significant structural differences with the most extensively studied family of receptor, the GPCR-A/rhodopsin family. Here, we try to summarize the current knowledge of the molecular mechanisms involved in VPAC(1) receptor activation and signal transduction. This includes search for amino acids involved in the two-step process of VIP binding, in the stabilization of VPAC(1) inactive and active conformations, and in binding and activation of G proteins.

摘要

血管活性肠肽受体 1(VPAC(1))属于 G 蛋白偶联受体家族 B,在结合血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽神经肽后被激活。VPAC(1)广泛分布于全身,在人体生理学和病理生理学中发挥着重要的调节作用。与大多数 G 蛋白偶联受体家族 B 成员一样,VPAC(1)受体被预测遵循天然配体作用的实际“双域”模型。然而,由于缺乏整个受体的 X 射线晶体结构,以及与研究最广泛的 G 蛋白偶联受体-A/视紫红质家族存在显著的结构差异,配体结合、受体激活和信号转导的确切结构基础仍不完全清楚。在这里,我们试图总结参与 VPAC(1)受体激活和信号转导的分子机制的最新知识。这包括寻找参与 VIP 结合的两步过程、稳定 VPAC(1)无活性和活性构象以及与 G 蛋白结合和激活的氨基酸。